Category Archives: Global News Feed

Please read the full announcement in PDF

View post:
Interim report for Q1 2022

Novozymes delivered solid earnings and double-digit organic sales growth in the first quarter of 2022. Despite negative effects of the tragic war in Ukraine the company increases its full-year organic sales growth from 3-7% to now 4-8%.

Read more:
Novozymes delivers strong 2022 Q1 results and raises full-year financial guidance

Sensor Measures Oxygen Levels Within Specific Human Tissue, Potentially Allowing Biosensor Feedback of Erectile Device Therapy Sensor Measures Oxygen Levels Within Specific Human Tissue, Potentially Allowing Biosensor Feedback of Erectile Device Therapy

Original post:
Petros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor...

Dr. Keefe to lead the product development and manufacturing of BlueSphere Bio’s first clinical candidate, a TCR T-cell therapy directed against the miHA HA-1. Dr. Keefe to lead the product development and manufacturing of BlueSphere Bio’s first clinical candidate, a TCR T-cell therapy directed against the miHA HA-1.

See the rest here:
BlueSphere Bio Appoints Robert Keefe, Ph.D. as Chief Development Officer

NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company developing alternative routes of immunotherapy with a focus on innovative drugs for neurodegenerative diseases, including treatment with intranasal foralumab for Secondary Progressive Multiple Sclerosis, today announced its Chief Executive Officer and Chief Scientific Officer, Kunwar Shailubhai, Ph.D., will participate in a fireside chat at the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference on Wednesday, April 27, 2022 at 2:30 p.m. ET (U.S. and Canada) to provide Company updates.

Continued here:
Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Excerpt from:
Sanofi: Information concerning the total number of voting rights and shares – March 2022